Pre-clinical and clinical development of the first placental malaria vaccine
暂无分享,去创建一个
[1] C. Wheeler,et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. , 2016, The Lancet. Infectious diseases.
[2] K. Moutairou,et al. Infections with Plasmodium falciparum during pregnancy affect VAR2CSA DBL-5 domain-specific T cell cytokine responses , 2016, Malaria Journal.
[3] Steve M. Taylor,et al. Scheduled Intermittent Screening with Rapid Diagnostic Tests and Treatment with Dihydroartemisinin-Piperaquine versus Intermittent Preventive Therapy with Sulfadoxine-Pyrimethamine for Malaria in Pregnancy in Malawi: An Open-Label Randomized Controlled Trial , 2016, PLoS medicine.
[4] R. Morrison,et al. VAR2CSA Domain-Specific Analysis of Naturally Acquired Functional Antibodies to Plasmodium falciparum Placental Malaria. , 2016, The Journal of infectious diseases.
[5] P. Damm,et al. Placental Sequestration of Plasmodium falciparum Malaria Parasites Is Mediated by the Interaction Between VAR2CSA and Chondroitin Sulfate A on Syndecan-1 , 2016, PLoS pathogens.
[6] T. Theander,et al. Adhesion of Plasmodium falciparum infected erythrocytes in ex vivo perfused placental tissue: a novel model of placental malaria , 2016, Malaria Journal.
[7] Joseph D. Smith,et al. Severe adult malaria is associated with specific PfEMP1 adhesion types and high parasite biomass , 2016, Proceedings of the National Academy of Sciences.
[8] C. Menéndez,et al. A Public Health Paradox: The Women Most Vulnerable to Malaria Are the Least Protected , 2016, PLoS medicine.
[9] T. Theander,et al. Bacterial superglue enables easy development of efficient virus-like particle based vaccines , 2016, Journal of Nanobiotechnology.
[10] B. Gamain,et al. Murine Model for Preclinical Studies of Var2CSA-Mediated Pathology Associated with Malaria in Pregnancy , 2016, Infection and Immunity.
[11] Steve M. Taylor,et al. Impact of Sulfadoxine-Pyrimethamine Resistance on Effectiveness of Intermittent Preventive Therapy for Malaria in Pregnancy at Clearing Infections and Preventing Low Birth Weight. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] O. Doumbo,et al. Non-falciparum malaria infections in pregnant women in West Africa , 2016, Malaria Journal.
[13] A. I. Barakat,et al. Computational Fluid Dynamic Simulations of Maternal Circulation: Wall Shear Stress in the Human Placenta and Its Biological Implications , 2016, PloS one.
[14] W. Moss,et al. Prevention of malaria in pregnancy: a fork in the road? , 2015, The Lancet.
[15] S. Kariuki,et al. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin–piperaquine versus intermittent preventive treatment with sulfadoxine–pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superi , 2015, The Lancet.
[16] M. Fried,et al. Designing a VAR2CSA-based vaccine to prevent placental malaria , 2015, Vaccine.
[17] T. Theander,et al. A Novel Virus-Like Particle Based Vaccine Platform Displaying the Placental Malaria Antigen VAR2CSA , 2015, PloS one.
[18] P. Sorensen,et al. Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein. , 2015, Cancer cell.
[19] A. Sabbagh,et al. Identification of a Major Dimorphic Region in the Functionally Critical N-Terminal ID1 Domain of VAR2CSA , 2015, PLoS ONE.
[20] T. Theander,et al. The Influence of Sub-Unit Composition and Expression System on the Functional Antibody Response in the Development of a VAR2CSA Based Plasmodium falciparum Placental Malaria Vaccine , 2015, PloS one.
[21] O. Doumbo,et al. A Non-Inferiority, Individually Randomized Trial of Intermittent Screening and Treatment versus Intermittent Preventive Treatment in the Control of Malaria in Pregnancy , 2015, PLoS ONE.
[22] S. C. T. P. Rts. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial , 2015, The Lancet.
[23] P. Deloron,et al. Developing vaccines to prevent malaria in pregnant women , 2015, Expert opinion on biological therapy.
[24] D. Lowy,et al. Raising expectations for subunit vaccine. , 2015, Journal of Infectious Diseases.
[25] Peter G. Kremsner,et al. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. , 2015 .
[26] T. Yeo,et al. Plasmodium knowlesi malaria during pregnancy. , 2015, The Journal of infectious diseases.
[27] U. Markert,et al. Only humans have human placentas: molecular differences between mice and humans. , 2015, Journal of reproductive immunology.
[28] C. King,et al. Parasite accumulation in placenta of non-immune baboons during Plasmodium knowlesi infection , 2015, Malaria Journal.
[29] A. Marconi,et al. Activation of Protein C in Human Trophoblasts in Culture and Downregulation of Trophoblast Endothelial Protein C Receptor by TNF-α , 2015, Reproductive Sciences.
[30] M. Molyneux,et al. Decreasing malaria prevalence and its potential consequences for immunity in pregnant women. , 2014, The Journal of infectious diseases.
[31] P. Garner,et al. Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment , 2014, The Cochrane database of systematic reviews.
[32] D. Garboczi,et al. Antigen Reversal Identifies Targets of Opsonizing IgGs against Pregnancy-Associated Malaria , 2014, Infection and Immunity.
[33] P. Walker,et al. Estimated risk of placental infection and low birthweight attributable to Plasmodium falciparum malaria in Africa in 2010: a modelling study. , 2014, The Lancet. Global health.
[34] A. Sabbagh,et al. Genetic diversity of VAR2CSA ID1-DBL2Xb in worldwide Plasmodium falciparum populations: impact on vaccine design for placental malaria. , 2014, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
[35] Victor A Alegana,et al. The changing risk of Plasmodium falciparum malaria infection in Africa: 2000–10: a spatial and temporal analysis of transmission intensity , 2014, The Lancet.
[36] K. Kain,et al. Functional Antibodies against VAR2CSA in Nonpregnant Populations from Colombia Exposed to Plasmodium falciparum and Plasmodium vivax , 2014, Infection and Immunity.
[37] J. Webster,et al. Coverage of intermittent preventive treatment and insecticide-treated nets for the control of malaria during pregnancy in sub-Saharan Africa: a synthesis and meta-analysis of national survey data, 2009-11. , 2013, The Lancet. Infectious diseases.
[38] P. Bigey,et al. Differential adhesion-inhibitory patterns of antibodies raised against two major variants of the NTS-DBL2X region of VAR2CSA. , 2013, Vaccine.
[39] C. Menéndez,et al. VAR2CSA Signatures of High Plasmodium falciparum Parasitemia in the Placenta , 2013, PloS one.
[40] P. Conzen,et al. Placental Syncytiotrophoblast Maintains a Specific Type of Glycocalyx at the Fetomaternal Border , 2013, Reproductive Sciences.
[41] D. Lowy,et al. Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses , 2013, Human vaccines & immunotherapeutics.
[42] T. Theander,et al. Malaria and Fetal Growth Alterations in the 3rd Trimester of Pregnancy: A Longitudinal Ultrasound Study , 2013, PloS one.
[43] David N. Olivieri,et al. Intravital Placenta Imaging Reveals Microcirculatory Dynamics Impact on Sequestration and Phagocytosis of Plasmodium-Infected Erythrocytes , 2013, PLoS pathogens.
[44] P. Bigey,et al. First-trimester Plasmodium falciparum infections display a typical "placental" phenotype. , 2012, The Journal of infectious diseases.
[45] C. Menéndez,et al. Placental infection with Plasmodium vivax: a histopathological and molecular study. , 2012, The Journal of infectious diseases.
[46] Joseph D. Smith,et al. Multilaboratory Approach to Preclinical Evaluation of Vaccine Immunogens for Placental Malaria , 2012, Infection and Immunity.
[47] S. Streatfield,et al. Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development , 2012, Vaccine.
[48] Thomas S. Rask,et al. Plasmodium falciparum erythrocyte membrane protein 1 domain cassettes 8 and 13 are associated with severe malaria in children , 2012, Proceedings of the National Academy of Sciences.
[49] T. Theander,et al. Structural and Functional Insight into How the Plasmodium falciparum VAR2CSA Protein Mediates Binding to Chondroitin Sulfate A in Placental Malaria* , 2012, The Journal of Biological Chemistry.
[50] N. Day,et al. Plasmodium vivax Adherence to Placental Glycosaminoglycans , 2012, PloS one.
[51] Dragana Nikitovic,et al. Glycosaminoglycans: key players in cancer cell biology and treatment , 2012, The FEBS journal.
[52] D. Scherman,et al. Identification of Id1-DBL2X of VAR2CSA as a key domain inducing highly inhibitory and cross-reactive antibodies. , 2012, Vaccine.
[53] D. Scherman,et al. The NTS-DBL2X region of VAR2CSA induces cross-reactive antibodies that inhibit adhesion of several Plasmodium falciparum isolates to chondroitin sulfate A. , 2011, The Journal of infectious diseases.
[54] P. Deloron,et al. Influence of the timing of malaria infection during pregnancy on birth weight and on maternal anemia in Benin. , 2011, The American journal of tropical medicine and hygiene.
[55] T. Theander,et al. Positive selection of Plasmodium falciparum parasites with multiple var2csa-type PfEMP1 genes during the course of infection in pregnant women. , 2011, The Journal of infectious diseases.
[56] B. Gamain,et al. Var2CSA Minimal CSA Binding Region Is Located within the N-Terminal Region , 2011, PloS one.
[57] P. Deloron,et al. Malaria associated symptoms in pregnant women followed-up in Benin , 2011, Malaria Journal.
[58] P. Andersen,et al. Differential Induction of Functional IgG Using the Plasmodium falciparum Placental Malaria Vaccine Candidate VAR2CSA , 2011, PloS one.
[59] T. Theander,et al. The Chondroitin Sulfate A-binding Site of the VAR2CSA Protein Involves Multiple N-terminal Domains , 2011, The Journal of Biological Chemistry.
[60] B. Gamain,et al. Antibodies to a Full-Length VAR2CSA Immunogen Are Broadly Strain-Transcendent but Do Not Cross-Inhibit Different Placental-Type Parasite Isolates , 2011, PloS one.
[61] T. Theander,et al. High efficacy of anti DBL4ɛ-VAR2CSA antibodies in inhibition of CSA-binding Plasmodium falciparum-infected erythrocytes from pregnant women. , 2011, Vaccine.
[62] D. Chandramohan,et al. Intermittent Screening and Treatment versus Intermittent Preventive Treatment of Malaria in Pregnancy: A Randomised Controlled Non-Inferiority Trial , 2010, PloS one.
[63] C. Lim,et al. Chondroitin Sulfate A-Adhering Plasmodium falciparum-Infected Erythrocytes Express Functionally Important Antibody Epitopes Shared by Multiple Variants , 2010, The Journal of Immunology.
[64] A. Scherf,et al. Strain-Transcendent Immune Response to Recombinant Var2CSA DBL5-ε Domain Block P. falciparum Adhesion to Placenta-Derived BeWo Cells under Flow Conditions , 2010, PloS one.
[65] Hong Zhou,et al. Subdomain 3 of Plasmodium falciparum VAR2CSA DBL3x Is Identified as a Minimal Chondroitin Sulfate A-binding Region* , 2010, The Journal of Biological Chemistry.
[66] S. Meshnick,et al. The effect of timing and frequency of Plasmodium falciparum infection during pregnancy on the risk of low birth weight and maternal anemia. , 2010, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[67] T. Theander,et al. Full-Length Recombinant Plasmodium falciparum VAR2CSA Binds Specifically to CSPG and Induces Potent Parasite Adhesion-Blocking Antibodies , 2010, Journal of molecular biology.
[68] B. Gamain,et al. Full-length extracellular region of the var2CSA variant of PfEMP1 is required for specific, high-affinity binding to CSA , 2010, Proceedings of the National Academy of Sciences.
[69] Joseph Bockhorst,et al. Evaluation of the Antigenic Diversity of Placenta-Binding Plasmodium falciparum Variants and the Antibody Repertoire among Pregnant Women , 2010, Infection and Immunity.
[70] T. Theander,et al. Several domains from VAR2CSA can induce Plasmodium falciparum adhesion-blocking antibodies , 2010, Malaria Journal.
[71] A. Tatem,et al. Quantifying the Number of Pregnancies at Risk of Malaria in 2007: A Demographic Study , 2010, PLoS medicine.
[72] M. Higgins,et al. Structural Comparison of Two CSPG-Binding DBL Domains from the VAR2CSA Protein Important in Malaria during Pregnancy , 2009, Journal of molecular biology.
[73] T. Theander,et al. Sequential, Ordered Acquisition of Antibodies to Plasmodium falciparum Erythrocyte Membrane Protein 1 Domains1 , 2009, The Journal of Immunology.
[74] T. Theander,et al. Chondroitin sulphate A (CSA)-binding of single recombinant Duffy-binding-like domains is not restricted to Plasmodium falciparum Erythrocyte Membrane Protein 1 expressed by CSA-binding parasites. , 2009, International journal for parasitology.
[75] Thomas Lavstsen,et al. Multiple var2csa-Type PfEMP1 Genes Located at Different Chromosomal Loci Occur in Many Plasmodium falciparum Isolates , 2009, PloS one.
[76] T. Theander,et al. Induction of Adhesion-Inhibitory Antibodies against Placental Plasmodium falciparum Parasites by Using Single Domains of VAR2CSA , 2009, Infection and Immunity.
[77] Shuhei Yamada,et al. Potential therapeutic application of chondroitin sulfate/dermatan sulfate. , 2008, Current drug discovery technologies.
[78] T. Theander,et al. VAR2CSA expression on the surface of placenta-derived Plasmodium falciparum-infected erythrocytes. , 2008, The Journal of infectious diseases.
[79] A. Gittis,et al. Structure of the DBL3x domain of pregnancy-associated malaria protein VAR2CSA complexed with chondroitin sulfate A , 2008, Nature Structural &Molecular Biology.
[80] M. Higgins,et al. The Structure of a Chondroitin Sulfate-binding Domain Important in Placental Malaria , 2008, Journal of Biological Chemistry.
[81] L. Gonçalves,et al. Pregnancy Outcome and Placenta Pathology in Plasmodium berghei ANKA Infected Mice Reproduce the Pathogenesis of Severe Malaria in Pregnant Women , 2008, PloS one.
[82] Joseph D. Smith,et al. Evidence for Globally Shared, Cross-Reacting Polymorphic Epitopes in the Pregnancy-Associated Malaria Vaccine Candidate VAR2CSA , 2008, Infection and Immunity.
[83] Ole Lund,et al. Structural Insight into Epitopes in the Pregnancy-Associated Malaria Protein VAR2CSA , 2008, PLoS pathogens.
[84] Joanne M. Chesson,et al. Structural Basis for Binding of Plasmodium falciparum Erythrocyte Membrane Protein 1 to Chondroitin Sulfate and Placental Tissue and the Influence of Protein Polymorphisms on Binding Specificity* , 2007, Journal of Biological Chemistry.
[85] M. Valiyaveettil,et al. Chondroitin sulfate proteoglycan but not hyaluronic acid is the receptor for the adherence of Plasmodium falciparum-infected erythrocytes in human placenta, and infected red blood cell adherence up-regulates the receptor expression. , 2007, The American journal of pathology.
[86] Gilles Cottrell,et al. The importance of the period of malarial infection during pregnancy on birth weight in tropical Africa. , 2007, The American journal of tropical medicine and hygiene.
[87] Gautam Aggarwal,et al. Patterns of gene recombination shape var gene repertoires in Plasmodium falciparum: comparisons of geographically diverse isolates , 2007, BMC Genomics.
[88] F. T. Ter Kuile,et al. Epidemiology and burden of malaria in pregnancy. , 2007, The Lancet. Infectious diseases.
[89] P. Andersen,et al. Human pregnancy-associated malaria-specific B cells target polymorphic, conformational epitopes in VAR2CSA , 2007, Molecular microbiology.
[90] B. Gamain,et al. Characterization of anti-var2CSA-PfEMP1 cytoadhesion inhibitory mouse monoclonal antibodies. , 2006, Microbes and infection.
[91] Ole Lund,et al. Epitope Mapping and Topographic Analysis of VAR2CSA DBL3X Involved in P. falciparum Placental Sequestration , 2006, PLoS pathogens.
[92] C. Chitnis,et al. Immunogenicity of Duffy Binding-Like Domains That Bind Chondroitin Sulfate A and Protection against Pregnancy-Associated Malaria , 2006, Infection and Immunity.
[93] M. Wahlgren,et al. Nonimmune immunoglobulin binding and multiple adhesion characterize Plasmodium falciparum-infected erythrocytes of placental origin , 2006, Proceedings of the National Academy of Sciences.
[94] M. Molyneux,et al. Transcribed var Genes Associated with Placental Malaria in MalawianWomen , 2006, Infection and Immunity.
[95] Philip Awadalla,et al. Global genetic diversity and evolution of var genes associated with placental and severe childhood malaria. , 2006, Molecular and biochemical parasitology.
[96] Stephen J Rogerson,et al. VAR2CSA is the principal ligand for chondroitin sulfate A in two allogeneic isolates of Plasmodium falciparum. , 2006, Molecular and biochemical parasitology.
[97] G. Domingo,et al. Plasmodium falciparum: chondroitin sulfate A is the major receptor for adhesion of parasitized erythrocytes in the placenta. , 2006, Experimental parasitology.
[98] C. Gamble,et al. Insecticide-treated nets for preventing malaria in pregnancy. , 2006, The Cochrane database of systematic reviews.
[99] M. Frank,et al. Mutually Exclusive Expression of Virulence Genes by Malaria Parasites Is Regulated Independently of Antigen Production , 2006, PLoS pathogens.
[100] Michael Lanzer,et al. A single member of the Plasmodium falciparum var multigene family determines cytoadhesion to the placental receptor chondroitin sulphate A , 2005, EMBO reports.
[101] T. Theander,et al. High level of var2csa transcription by Plasmodium falciparum isolated from the placenta. , 2005, The Journal of infectious diseases.
[102] B. Gamain,et al. Identification of multiple chondroitin sulfate A (CSA)-binding domains in the var2CSA gene transcribed in CSA-binding parasites. , 2005, The Journal of infectious diseases.
[103] John R Yates,et al. A Comprehensive Survey of the Plasmodium Life Cycle by Genomic, Transcriptomic, and Proteomic Analyses , 2005, Science.
[104] P. Deloron,et al. Variable adhesion abilities and overlapping antigenic properties in placental Plasmodium falciparum isolates. , 2004, The Journal of infectious diseases.
[105] Thor G. Theander,et al. Evidence for the Involvement of VAR2CSA in Pregnancy-associated Malaria , 2004, The Journal of experimental medicine.
[106] D. Gowda,et al. Plasmodium falciparum-infected erythrocytes adhere both in the intervillous space and on the villous surface of human placenta by binding to the low-sulfated chondroitin sulfate proteoglycan receptor. , 2004, The American journal of pathology.
[107] S. Sharp,et al. Plasmodium falciparum Associated with Severe Childhood Malaria Preferentially Expresses PfEMP1 Encoded by Group A var Genes , 2004, The Journal of experimental medicine.
[108] I. Crocker,et al. Syncytiotrophoblast degradation and the pathophysiology of the malaria-infected placenta. , 2004, Placenta.
[109] M. Avril,et al. Placenta cryosections for study of the adhesion of Plasmodium falciparum-infected erythrocytes to chondroitin sulfate A in flow conditions. , 2004, Microbes and infection.
[110] O. Branch,et al. Antibodies That Inhibit Binding of Plasmodium falciparum-Infected Erythrocytes to Chondroitin Sulfate A and to the C Terminus of Merozoite Surface Protein 1 Correlate with Reduced Placental Malaria in Cameroonian Women , 2004, Infection and Immunity.
[111] Kevin Marsh,et al. Variant surface antigen-specific IgG and protection against clinical consequences of pregnancy-associated Plasmodium falciparum malaria , 2004, The Lancet.
[112] M. Fried,et al. Antibodies That Inhibit Plasmodium falciparum Adhesion to Chondroitin Sulfate A Are Associated with Increased Birth Weight and the Gestational Age of Newborns , 2003, Infection and Immunity.
[113] Thomas Lavstsen,et al. Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A‐adhering Plasmodium falciparum involved in pregnancy‐associated malaria , 2003, Molecular microbiology.
[114] Jonathan E. Allen,et al. Genome sequence of the human malaria parasite Plasmodium falciparum , 2002, Nature.
[115] M. Valiyaveettil,et al. Gravidity-Dependent Production of Antibodies That Inhibit Binding of Plasmodium falciparum-Infected Erythrocytes to Placental Chondroitin Sulfate Proteoglycan during Pregnancy , 2001, Infection and Immunity.
[116] M. Wahlgren,et al. Role of Nonimmune IgG Bound to PfEMP1 in Placental Malaria , 2001, Science.
[117] R. Leke,et al. Acquisition and decay of antibodies to pregnancy-associated variant antigens on the surface of Plasmodium falciparum-infected erythrocytes that protect against placental parasitemia. , 2001, The Journal of infectious diseases.
[118] M. Valiyaveettil,et al. Characterization of Proteoglycans of Human Placenta and Identification of Unique Chondroitin Sulfate Proteoglycans of the Intervillous Spaces That Mediate the Adherence ofPlasmodium falciparum-infected Erythrocytes to the Placenta* , 2000, The Journal of Biological Chemistry.
[119] T. Theander,et al. Plasma Antibodies from Malaria-Exposed Pregnant Women Recognize Variant Surface Antigens on Plasmodium falciparum-Infected Erythrocytes in a Parity-Dependent Manner and Block Parasite Adhesion to Chondroitin Sulfate A1 , 2000, The Journal of Immunology.
[120] J. Simpson,et al. Effects of Plasmodium vivax malaria in pregnancy , 1999, The Lancet.
[121] M. Galinski,et al. Antigenic variation in malaria: a 3' genomic alteration associated with the expression of a P. knowlesi variant antigen. , 1999, Molecular cell.
[122] François Nosten,et al. Maternal antibodies block malaria , 1998, Nature.
[123] A. Scherf,et al. Antigenic variation in malaria: in situ switching, relaxed and mutually exclusive transcription of var genes during intra‐erythrocytic development in Plasmodium falciparum , 1998, The EMBO journal.
[124] C. Menéndez,et al. Massive chronic intervillositis of the placenta associated with malaria infection. , 1998, The American journal of surgical pathology.
[125] Mats Wahlgren,et al. Developmental selection of var gene expression in Plasmodium falciparum , 1998, Nature.
[126] Kevin Marsh,et al. Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria , 1998, Nature Medicine.
[127] R. Coppel,et al. Adhesion of malaria-infected red blood cells to chondroitin sulfate A under flow conditions. , 1996, Blood.
[128] Patrick E. Duffy,et al. Adherence of Plasmodium falciparum to Chondroitin Sulfate A in the Human Placenta , 1996, Science.
[129] Theodore F. Taraschi,et al. Cloning the P. falciparum gene encoding PfEMP1, a malarial variant antigen and adherence receptor on the surface of parasitized human erythrocytes , 1995, Cell.
[130] Joseph D. Smith,et al. Switches in expression of plasmodium falciparum var genes correlate with changes in antigenic and cytoadherent phenotypes of infected erythrocytes , 1995, Cell.
[131] X. Su,et al. The large diverse gene family var encodes proteins involved in cytoadherence and antigenic variation of plasmodium falciparum-infected erythrocytes , 1995, Cell.
[132] R. Steketee,et al. Plasmodium falciparum associated placental pathology: a light and electron microscopic and immunohistologic study. , 1989, The American journal of tropical medicine and hygiene.
[133] E. Peterson,et al. Pathogenicity, stability, and immunogenicity of a knobless clone of Plasmodium falciparum in Colombian owl monkeys , 1985, Infection and immunity.
[134] L. Miller,et al. Parasite sequestration in Plasmodium falciparum malaria: spleen and antibody modulation of cytoadherence of infected erythrocytes. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[135] J. Barnwell,et al. Antigenic variation of Plasmodium knowlesi malaria: identification of the variant antigen on infected erythrocytes. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[136] Y. Garin,et al. Placental pathologic changes in malaria. A histologic and ultrastructural study. , 1982, The American journal of pathology.
[137] G. Saunders,et al. The treatment of malaria. , 1947, Missouri medicine.
[138] A. Salanti,et al. High-Throughput Testing of Antibody-Dependent Binding Inhibition of Placental Malaria Parasites. , 2015, Methods in molecular biology.
[139] M. Fried,et al. Evaluation of Pregnancy Malaria Vaccine Candidates: The Binding Inhibition Assay. , 2015, Methods in molecular biology.
[140] Organización Mundial de la Salud. Guidelines for the treatment of malaria , 2010 .
[141] M. Molyneux,et al. Placental monocyte infiltrates in response to Plasmodium falciparum malaria infection and their association with adverse pregnancy outcomes. , 2003, The American journal of tropical medicine and hygiene.
[142] M. Molyneux,et al. Adhesion of Plasmodium falciparum-infected erythrocytes to hyaluronic acid in placental malaria , 2000, Nature Medicine.
[143] C. Menéndez,et al. Placental pathology in malaria: a histological, immunohistochemical, and quantitative study. , 2000, Human pathology.
[144] H. Fox,et al. The human materno-foetal relationship in malaria. II. Histological, ultrastructural and immunopathological studies of the placenta. , 1980, Transactions of the Royal Society of Tropical Medicine and Hygiene.